Rubin P, McDonald S, Maasilta P, Finkelstein J N, Shapiro D L, Penney D, Gregory P K
Dept. Radiation Oncology, University of Rochester Cancer Center, NY.
Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):553-8. doi: 10.1016/0360-3016(89)90106-5.
Detection of a biochemical marker indicating radiation lung injury prior to the onset of clinical pathologic events could prove valuable in patient management. An increased level of alveolar surfactant is one of the earliest detectable changes following lung irradiation, starting within hours of irradiation and persisting a maximum of 2-6 weeks. However, because broncho-alveolar lavage is impracticable and endothelial cell damage due to radiation results in changes in permeability of vessel wall with leakage of alveolar proteins into serum, identification of serum markers was sought. A series of experiments in rabbits are described that clearly demonstrate serum surfactant apoprotein is an accurate marker and predictor for later lethal radiation pneumonitis. At 3-7 days after graded single doses to lung, surfactant was found in the serum paralleling the dose response for lethality. Control studies with a physiologic agent such as terbutaline release alveolar surfactant, but no serum surfactant was detected. Monitoring serum surfactant could direct preventive intervention prior to clinicopathologic manifestation of pulmonary radiation syndromes.
在临床病理事件发生之前检测到表明放射性肺损伤的生化标志物,可能对患者管理具有重要价值。肺泡表面活性物质水平升高是肺部照射后最早可检测到的变化之一,在照射后数小时内开始出现,并最多持续2 - 6周。然而,由于支气管肺泡灌洗不切实际,且辐射导致的内皮细胞损伤会引起血管壁通透性改变,使肺泡蛋白漏入血清,因此人们寻求鉴定血清标志物。本文描述了一系列在兔子身上进行的实验,这些实验清楚地表明血清表面活性物质载脂蛋白是晚期致死性放射性肺炎的准确标志物和预测指标。在对肺部进行分级单次剂量照射后3 - 7天,血清中发现了表面活性物质,其与致死率的剂量反应平行。使用诸如特布他林等生理制剂的对照研究可释放肺泡表面活性物质,但未检测到血清表面活性物质。监测血清表面活性物质可在肺部辐射综合征的临床病理表现出现之前指导预防性干预。